| Mar 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | ||
|---|---|---|---|---|---|---|---|
| Total Revenues ($Mil): | 0.57 | 0.58 | 0.01 | 0.01 | 0.00 | 0.01 | |
| Depreciation & Amort ($Mil): | 0.73 | 0.73 | 0.27 | 0.14 | |||
| Operating Income ($Mil): | -11.52 | -13.64 | -5.80 | -2.57 | N/C | N/C | |
| Net Income ($Mil): | -15.06 | -12.90 | -5.61 | -3.63 | -0.07 | ||
| Earnings Per Share ($): | -0.21 | -0.20 | -0.11 | -0.09 | 0.00 | 0.00 | |
| Dividends ($): | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Mar 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | ||
|---|---|---|---|---|---|---|---|
| Current Assets ($Mil): | 29.93 | 33.98 | 3.24 | 6.50 | |||
| Current Liabilities ($Mil): | 2.38 | 2.71 | 1.08 | 0.55 | |||
| Long Term Debt ($Mil): | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Shares Outstanding (000): | 76340 | 76040 | 0 | 0 | 0 | 0 | 0 |
| Common Equity ($Mil): | 31.31 | 34.92 | 3.49 | 6.20 |
| Mar 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | ||
|---|---|---|---|---|---|---|---|
| Profit Margin (%): | -2642.11 | -2224.14 | -56100.00 | -36300.00 | 0.00 | -600.00 | 0.00 |
| Return on Equity (%): | -55.82 | -36.94 | -160.74 | -58.55 | 0.00 | 0.00 | 0.00 |
| Return on Assets (%): | -50 | -33.81 | -112.88 | -51.20 | 0.00 | 0.00 | 0.00 |
| P/E Ratio: | 0 | -18.95 | -11.00 | -314.56 | 0.00 | 0.00 | 0.00 |
| Price/Book: | 3 | 8.25 | 0.00 | 0.00 | NaN | NaN | NaN |
| Debt Equity: | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage: | 0.00 | -160.13 | -139.25 | -50.86 | 0.00 | 0.00 | 0.00 |
| Book Value ($): | 0.41 | 0.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price/Sales: | 191.41 | 140.63 | 0.00 | 0.00 | NaN | 0.00 | NaN |
| Dividend Payout (%): | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |

| AMGEN | +46.20 | 65.06 | |
| GILEAD SCIENCES | +45.50 | 56.26 | |
| GENENTECH INC | +47.20 | 98.23 | |
| BIOGEN IDEC INC | -1.20 | 54.65 | |
| CELGENE CP | +36.60 | 75.86 |
